Correlation Between BridgeBio Pharma and Cytodyn

Can any of the company-specific risk be diversified away by investing in both BridgeBio Pharma and Cytodyn at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining BridgeBio Pharma and Cytodyn into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between BridgeBio Pharma and Cytodyn, you can compare the effects of market volatilities on BridgeBio Pharma and Cytodyn and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in BridgeBio Pharma with a short position of Cytodyn. Check out your portfolio center. Please also check ongoing floating volatility patterns of BridgeBio Pharma and Cytodyn.

Diversification Opportunities for BridgeBio Pharma and Cytodyn

0.2

Correlation Coefficient

BridgeBio Pharma  Cytodyn

Modest diversification

The 3 months correlation between BridgeBio and Cytodyn is 0.2. Overlapping area represents the amount of risk that can be diversified away by holding BridgeBio Pharma and Cytodyn in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cytodyn and BridgeBio Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on BridgeBio Pharma are associated (or correlated) with Cytodyn. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cytodyn has no effect on the direction of BridgeBio Pharma i.e., BridgeBio Pharma and Cytodyn go up and down completely randomly.

Pair Corralation between BridgeBio Pharma and Cytodyn

Given the investment horizon of 90 days BridgeBio Pharma is expected to generate 0.82 times more return on investment than Cytodyn. However, BridgeBio Pharma is 1.23 times less risky than Cytodyn. It trades about -0.01 of its potential returns per unit of risk. Cytodyn is currently generating about -0.11 per unit of risk. If you would invest  3,070  in BridgeBio Pharma on September 9, 2024 and sell it today you would lose (191.00) from holding BridgeBio Pharma or give up 6.22% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

BridgeBio Pharma  vs.  Cytodyn

BridgeBio Pharma

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days BridgeBio Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy forward indicators, BridgeBio Pharma is not utilizing all of its potentials. The latest stock price disarray, may contribute to short-term losses for the investors.

Cytodyn

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Cytodyn has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's fundamental indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with BridgeBio Pharma and Cytodyn

The main advantage of trading using opposite BridgeBio Pharma and Cytodyn positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if BridgeBio Pharma position performs unexpectedly, Cytodyn can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cytodyn will offset losses from the drop in Cytodyn's long position.

The idea behind BridgeBio Pharma and Cytodyn pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.